
Victor Sanchez-Merino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2107700/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses. Journal of Virology, 2022, 96, JVI0134321.	3.4	10
2	Evaluation of the Thermal Stability of a Vaccine Prototype Based on Virus-like Particle Formulated HIV-1 Envelope. Vaccines, 2022, 10, 484.	4.4	2
3	Permanent control of HIV-1 pathogenesis in exceptional elite controllers: a model of spontaneous cure. Scientific Reports, 2020, 10, 1902.	3.3	50
4	Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant. PLoS ONE, 2018, 13, e0208345.	2.5	8
5	Lipid raft-like liposomes used for targeted delivery of a chimeric entry-inhibitor peptide with anti-HIV-1 activity. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 601-609.	3.3	9
6	Antibody-Based Preventive and Therapeutic Strategies Against HIV. Current HIV Research, 2016, 14, 260-269.	0.5	1
7	HIV-1 Dual Infected LTNP-EC Patients Developed an Unexpected Antibody Cross-Neutralizing Activity. PLoS ONE, 2015, 10, e0134054.	2.5	5
8	Evolution of Broadly Cross-Reactive HIV-1-Neutralizing Activity: Therapy-Associated Decline, Positive Association with Detectable Viremia, and Partial Restoration of B-Cell Subpopulations. Journal of Virology, 2013, 87, 12227-12236.	3.4	18
9	Influenza, but not HIVâ€specific CTL epitopes, elicits delayedâ€type hypersensitivity (DTH) reactions in HIVâ€infected patients. European Journal of Immunology, 2013, 43, 1545-1554.	2.9	1
10	HIV-1 Inhibiting Capacity of Novel Forms of Presentation of GB Virus C Peptide Domains is Enhanced by Coordination to Gold Compounds. Current Medicinal Chemistry, 2013, 21, 238-250.	2.4	8
11	Low-Replicating Viruses and Strong Anti-Viral Immune Response Associated with Prolonged Disease Control in a Superinfected HIV-1 LTNP Elite Controller. PLoS ONE, 2012, 7, e31928.	2.5	21
12	Definition of the viral targets of protective HIV-1-specific T cell responses. Journal of Translational Medicine, 2011, 9, 208.	4.4	143
13	Human Immunodeficiency Virus Type 1 and Related Primate Lentiviruses Engage Clathrin through Gag-Pol or Gag. Journal of Virology, 2011, 85, 3792-3801.	3.4	17
14	Programmed Death-1 Expression on Epstein Barr Virus Specific CD8+ T Cells Varies by Stage of Infection, Epitope Specificity, and T-Cell Receptor Usage. PLoS ONE, 2010, 5, e12926.	2.5	35
15	Identification of Ongoing Human Immunodeficiency Virus Type 1 (HIV-1) Replication in Residual Viremia during Recombinant HIV-1 Poxvirus Immunizations in Patients with Clinically Undetectable Viral Loads on Durable Suppressive Highly Active Antiretroviral Therapy. Journal of Virology, 2009, 83, 9731-9742.	3.4	41
16	Identification and Characterization of HIVâ€1 CD8+T Cell Escape Variants with Impaired Fitness. Journal of Infectious Diseases, 2008, 197, 300-308.	4.0	19
17	Genetic Changes Associated with Distinct Patterns of HIV Type 1 Persistence in Chronically Infected Cell Lines. AIDS Research and Human Retroviruses, 2007, 23, 251-260.	1.1	3
18	HIV-1-Specific CD8+ T Cell Responses and Viral Evolution in Women and Infants. Journal of Immunology, 2005, 175, 6976-6986.	0.8	28

#	Article	IF	CITATIONS
19	Genetic Analysis of Culture-Negative UNAIDS Subtype C Samples. AIDS Research and Human Retroviruses, 2003, 19, 49-55.	1.1	9
20	Resistance to Nucleoside Analog Reverse Transcriptase Inhibitors Mediated by Human Immunodeficiency Virus Type 1 p6 Protein. Journal of Virology, 2001, 75, 9644-9653.	3.4	73